Globus Medical Inc (NYSE: GMED) has a higher price-to-earnings ratio of 45.31x compared to its average ratio. GMED has 36-month beta value of 1.21. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 5 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for GMED is 112.29M, and currently, short sellers hold a 4.13% ratio of that float. The average trading volume of GMED on July 03, 2025 was 1.47M shares.
GMED) stock’s latest price update
The stock of Globus Medical Inc (NYSE: GMED) has increased by 0.61% when compared to last closing price of $60.2. Despite this, the company has experienced a 4.09% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-22 that NEW YORK, June 22, 2025 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
GMED’s Market Performance
Globus Medical Inc (GMED) has seen a 4.09% rise in stock performance for the week, with a 2.73% gain in the past month and a -17.47% plunge in the past quarter. The volatility ratio for the week is 2.40%, and the volatility levels for the past 30 days are at 2.02% for GMED. The simple moving average for the past 20 days is 2.23% for GMED’s stock, with a -19.12% simple moving average for the past 200 days.
Analysts’ Opinion of GMED
BofA Securities, on the other hand, stated in their research note that they expect to see GMED reach a price target of $97. The rating they have provided for GMED stocks is “Neutral” according to the report published on January 10th, 2025.
Morgan Stanley gave a rating of “Overweight” to GMED, setting the target price at $100 in the report published on December 02nd of the previous year.
GMED Trading at -3.02% from the 50-Day Moving Average
After a stumble in the market that brought GMED to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.20% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GMED starting from RHOADS ANN D, who sale 7,500 shares at the price of $78.68 back on Feb 28 ’25. After this action, RHOADS ANN D now owns 35,384 shares of Globus Medical Inc, valued at $590,100 using the latest closing price.
Stock Fundamentals for GMED
Current profitability levels for the company are sitting at:
- 0.11 for the present operating margin
- 0.57 for the gross margin
The net margin for Globus Medical Inc stands at 0.07. The total capital return value is set at 0.06. Equity return is now at value 4.63, with 3.84 for asset returns.
Based on Globus Medical Inc (GMED), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 6.99. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 86.66.
Currently, EBITDA for the company is 378.94 million with net debt to EBITDA at -0.76. When we switch over and look at the enterprise to sales, we see a ratio of 3.12. The receivables turnover for the company is 4.67for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.45.
Conclusion
To put it simply, Globus Medical Inc (GMED) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
